Cancer Immunogene Therapy. Anti – gene anti IGF-I approach. Case of Glioblastoma

      Аннотация: Certain specific antigens, which behave as oncoproteins, are present in normal fetal/neonatal developing brain. It was demonstrated that a convergence exists between ontogenesis and onco-genesis. The most malignant example of central nervous system neoplasia is glioblastoma multiforme. The biomarker – oncoprotein - characteristic of glial fetal and tumoral cells, but not neuronal cells, is IGF-I. For this reason, for therapy purpose, the arrest of IGF-I synthesis in cancer glial cells of glioblastoma was performed using in vitro anti – gene anti IGF-I strategy (IGF-I antisense /triple helix, AS/TH). The created AS/TH cells, became immunogenic and expressed MHC-I, B71 antigens. The AS/TH cells while injected in glioblastoma patients, induced the antitumor immune response and stopped the progression of tumor development. The survival of treated glioblastoma patients reached 2 years, and in some cases, up to 3-4 years. The established Anti - Gene IGF-I cancer immunotherapy was introduced in USA, Europe, China and Latin America.

Ключевые слова: Cancer Immunotherapy